X

Drug Profile

DFI 105

Alternative Names: DFI-105

Latest Information Update: 04 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator DIABETES FREE
Class Monoclonal antibodies
Mechanism of Action CD40 antigen inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Multiple sclerosis

Most Recent Events

18 Feb 2025 Preclinical trials in Multiple sclerosis in USA (SC), prior to February 2025 (Diabetes Free pipeline, February 2025)
18 Feb 2025 Diabetes Free plans a phase II trial for Multiple sclerosis (SC) in Q1 2025 (Diabetes Free pipeline, February 2025)
12 May 2022 Diabetes-free has patents pending for DFI 105 in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com